Jolt Health Inc. Acquires Revolutionary HCQ Transdermal Patch Technology

Jolt Health Inc., a prominent biotechnology firm, announced an acquisition of intellectual property for developing transdermal delivery systems for hydroxychloroquine (HCQ) and chloroquine (CQ), targeting the management of malaria, lupus, and rheumatoid arthritis. With an arms-length agreement dated April 16, 2024, this acquisition aims to enhance Jolt’s health and wellness portfolio significantly.

The technology involves transdermal and oral mucosal delivery methods that could potentially tackle common side effects associated with the current oral tablet form of HCQ, such as nausea and dizziness. By bypassing the gastrointestinal system, this new method promises a safer, more consistent dosage that could vastly improve patient outcomes.

Jolt Health plans to pursue FDA approval for this technology through the 505(b)(2) accelerated pathway. The market implications are substantial, with the HCQ market projected to attain $6 billion by 2027. This initiative marks a strategic expansion in Jolt Health’s biotechnology assets, focusing on better service delivery and patient care in underaddressed ailments.